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Background-—Brain-derived neurotrophic factor (BDNF) is a pleiotropic peptide involved in maintaining endothelial integrity. It is
unknown if circulating BDNF levels are associated with risk of cardiovascular disease (CVD).
Methods and Results-—We prospectively investigated the association of circulating BDNF levels with cardiovascular events and
mortality in 3687 participants (mean age 65 years, 2068 women) from the Framingham Heart Study (FHS). Using a common
nonsynonomous single nucleotide polymorphism (SNP) in the BDNF gene (rs6265), we then performed a Mendelian randomization
experiment in the CARDIoGRAM (Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis) consortium (>22 000
coronary artery disease [CAD] cases, >60 000 controls) to investigate whether SNP rs6265 was associated with CAD in
CARDIoGRAM and, if so, whether the effect estimate differed from that predicted based on FHS data. On follow-up (median
8.9 years), 467 individuals (261 women) in FHS experienced a CVD event, and 835 (430 women) died. In multivariable-adjusted
Cox regression, serum BDNF was associated inversely with CVD risk (hazard ratio [HR] per 1-SD increase 0.88, 95% CI 0.80 to
0.97, P=0.01) and with mortality (HR 0.87, 95% CI 0.80 to 0.93, P=0.0002). SNP rs6265 was associated with BDNF concentrations
(0.772 ng/mL increase per minor allele copy) in FHS. In CARDIoGRAM, SNP rs6265 was associated with CAD (odds ratio 0.957,
95% CI 0.923 to 0.992), a magnitude consistent with the predicted effect (HR per minor allele copy 0.99, 95% CI 0.98 to 1.0;
P=0.06 for difference between predicted and observed effect).
Conclusion-—Higher serumBDNF is associatedwith a decreased risk of CVDandmortality. Mendelian randomization suggests a causal
protective role of BDNF in the pathogenesis of CVD. ( J Am Heart Assoc. 2015;4:e001544 doi: 10.1161/JAHA.114.001544)
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C ardiovascular disease (CVD) is the leading cause ofdeath in the developed countries, and clinical risk factors
for CVD (eg, obesity, dyslipidemia, diabetes, and a sedentary
lifestyle) have been known for decades. Nevertheless, the
molecular basis of CVD is complex and linked to a broad range
of biological pathways, including lipid and glucose metabolism,
inﬂammation, vascular repair, and angiogenesis. Brain-derived
neurotrophic factor (BDNF) is a pleiotropic peptide mediator
involved in the regulation of appetite and physical activity and in
neuroplasticity.1 Heterozygous BDNF knockout mice consume
almost 50% more food than do their wild-type littermates and
are obese.2 Independent of its effect on energy homeostasis,
BDNF has been implicated in angiogenesis and the mainte-
nance of vascular integrity in recent reports.3 Thus, conditional
BDNF knockout mice have greater myocardial damage after
experimental infarction compared with wild-type mice.4 These
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observations raise the possibility that BDNF may play a role in
the pathogenesis of CVD.
Indeed, limited epidemiological data suggest that higher
circulating BDNF levels may be associated with a lower
prevalence of cardiovascular risk factors and with a lower
mortality in small samples.5,6 Conversely, patients with
unstable angina have been reported to have increased BDNF
levels in the coronary circulation compared with individuals
with stable angina, suggesting that BDNF may detrimentally
inﬂuence plaque stability.7 Taken together, epidemiological
data on the relation between BDNF and CVD are sparse and
conﬂicting. Thus, we prospectively investigated the associa-
tion of circulating BDNF levels with cardiovascular events and
mortality in the community-based Framingham Heart Study
(FHS) cohort. To assess a potentially causal relation between
BDNF levels and CVD, we performed a Mendelian randomi-
zation analysis by using the CARDIoGRAM (Coronary ARtery
DIsease Genome-Wide Replication And Meta-Analysis) meta-
sample.
Methods
Study Samples
Framingham Heart Study (FHS)
The FHS sample for the present investigation was derived
from the Original and Offspring cohorts8,9 and is based on
the 23rd FHS Original cohort examination (1992–1996) and
the 7th Offspring cohort examination (1998–2001). The FHS
started in 1948 with the recruitment of 5209 individuals
from the general population residing in the Framingham, MA,
area, referred to as the Original cohort. Participants in this
cohort are evaluated at the FHS clinic approximately every
2 years, including a detailed medical history, physical
examination, blood pressure assessment, ECG, and phlebot-
omy for the measurement of vascular risk factors. The
Framingham Offspring study began in 1971 with the
recruitment of 5124 individuals who were the offspring of
the Original Cohort or the offsprings’ spouses.9 Follow-up
examinations in the study clinic are performed approximately
once every 4 years.
Of 1026 Original cohort participants attending examination
cycle 23, we excluded 357 who did not have available BDNF
measurements (>225 participants had visits at home and
blood was not drawn; additionally, serum samples drawn in
the ﬁrst 4 months of the examination cycle were not available
for this assay due to storage-related problems). Of 3539
Offspring cohort participants attending examination cycle 7,
we excluded 3 participants for lack of follow-up data and an
additional 518 who did not have available BDNF measure-
ments (due to lack of sufﬁcient amounts of serum aliquots),
resulting in a ﬁnal sample size of 3687 (669 Original cohort,
3018 Offspring cohort participants).
Physical activity was assessed (in the Offspring cohort
only) by using a structured questionnaire and then quantiﬁed
as a physical activity index, which is calculated based on
weighted frequencies and duration of the reported activities
as detailed previously.10 Depression was assessed (in the
Offspring cohort only) using the Center for Epidemiological
Studies–Depression Scale (CESD), which is an accepted tool
to screen for depressive symptoms in observational cohort
settings.11
The study was approved by the Boston University Medical
Center Institutional Review Board; written informed consent
was obtained from all participants.
Biomarker measurements in the FHS cohort
Serum BDNF levels were determined by using Quantikine
ELISA kits obtained from R&D Systems after a 20-fold dilution
in polypropylene tubes with Calibrator Diluent RD6P included
in the kits. The sensitivity of the assay is estimated to be at or
below 0.0625 ng/mL. The intra- and inter-assay coefﬁcients
of variation were 3.8% to 6.2% and 7.6% to 11.3%, respec-
tively. High-sensivity C-reactive protein (hsCRP) was mea-
sured (only in the Offspring cohort) by using a nephelometer
(Dade Behring).12 Brain natriuretic peptide (BNP) was mea-
sured only in the Offspring cohort at examination cycle 6 (not
7), by using an immunoradiometric assay (Shionogi) as
previously described.13
Genotyping in FHS
Single nucleotide polymorphism (SNP) rs6265 was directly
genotyped on the Illumina Beadstation 500G genotyping
system by using Illumina FastTrack Services and the Golden
Gate assay workﬂow protocol. The sample success rate was
99.44%, locus success rate was 97.4%, genotype call rate
was 99.72%, reproducibility was 100%, and Mendelian
consistency 99.99%. Minor allele frequency of rs6265
was 0.19 in FHS. Genotypes are available at http://
www.ncbi.nlm.nih.gov/gap.
Outcome events in FHS
A “cardiovascular event” was deﬁned as angina pectoris,
coronary insufﬁciency (prolonged angina with documented
ECG changes), myocardial infarction, stroke (ischemic or
hemorrhagic) or transient ischemic attack, incident heart
failure, intermittent claudication, or death secondary to
CVD. All cardiovascular events were adjudicated by a panel
of 2 or 3 investigators on review of hospital records,
medical ofﬁce notes, and Framingham clinic visit notes, by
using standardized criteria that have been described
previously.14
DOI: 10.1161/JAHA.114.001544 Journal of the American Heart Association 2
Circulating BDNF and Cardiovascular Disease Kaess et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Mendelian randomization in the CARDIoGRAM meta-
sample
We assessed the association of the major functional genetic
variant within the BDNF gene (rs6265) with coronary artery
disease (CAD) in the CARDIoGRAM consortium.15 CARDIo-
GRAM is a meta-analysis of genome-wide association data for
CAD including myocardial infarction and consists of 14
population-based cohorts and case-control samples, including
in total >22 000 cases and >60 000 controls.15 We chose
CARDIoGRAM for our Mendelian randomization experiment
because it is the largest consortium of CAD outcomes with
availability of genetic data for the BDNF locus, thereby
maximizing our statistical power. We are unaware of larger
consortia that have evaluated a composite outcome of CVD
(paralleling our primary outcome in FHS) or consortia that
have assessed all-cause mortality in a genome-wide context
with availability of BDNF SNP data. Minor allele frequency of
SNP rs6265 was 0.18 in CARDIoGRAM.
Statistical Analyses
BDNF levels were normally distributed. Age- and sex-adjusted
incidence rates of CVD and all-cause mortality across quartiles
of serum BDNF were calculated by using direct standardization
by sex and age strata of <60, 60 to 74 and ≥75 years. We then
estimated Cox proportional hazards regression models to
further explore the relation of BDNF with CVD incidence and all-
cause mortality after conﬁrming the assumption of proportion-
ality of hazards for both outcomes. We assessed 2 models: (1)
adjusting only for age and sex and (2) additionally adjusting for
standard CVD risk factors16 (ie, age, sex, smoking, systolic
blood pressure, hypertension treatment, total and high-density
lipoprotein cholesterol, diabetes mellitus, and body mass index
[BMI]). All models were stratiﬁed by study cohort (Original
versus Offspring). We adjusted for BMI (although it has been an
inconsistent component of CVD risk prediction algorithms)
because of the potential association of BDNF with BMI.17 Using
interaction terms, we assessed potential effect modiﬁcation by
age, BMI, or study cohort in our multivariable models. However,
these terms were statistically nonsigniﬁcant (all P>0.05 for
both outcomes). To further explore any potential nonlinear
relation of BDNF levels with CVD events and mortality, we
constructed multivariable-adjusted (covariates of model 2)
nonparametric restricted cubic splines (with 3 knots at the
quartiles of the BDNF distribution).18 To further assess a
potential role of smoking, we adjusted our multivariable models
for lifetime smoking exposure in pack-years (instead of current
smoking status). We also investigated whether current smoking
modiﬁes the relation between serum BDNF and events by
introducing an interaction term (smoking9BDNF) into our
multivariable models.
In exploratory analyses, we additionally adjusted our Cox
models for other novel CVD biomarkers (ie, hsCRP and
BNP) and for physical activity (by using the physical activity
index) and depression (using the CESD score). These
analyses were limited to the Offspring cohort because
these variables were measured only in this cohort. All
analyses were performed by using SAS version 9.2 (SAS
Institute). A P value of <0.05 was considered statistically
signiﬁcant.
To assess the contribution of BDNF levels to CVD risk
prediction, we compared performance metrics of a model
incorporating standard CVD risk factors (multivariable Cox
regression model 2) to a model that additionally included
serum BDNF. We assessed increment in the c-statistic, the
integrated discrimination improvement (IDI), and the contin-
uous net reclassiﬁcation improvement (NRI), all calculated as
previously described.19,20
Table 1. Characteristics of the Study Sample
Characteristics Total (N=3687)
Age, y 6511
Women, n (%) 2068 (56.1)
Body mass index, kg/m2 27.95.2
Systolic blood pressure, mm Hg 13020
Diastolic blood pressure, mm Hg 7310
Antihypertensive medication, n (%) 1354 (36.8)
Total cholesterol, mg/dL 20137
HDL cholesterol, mg/dL 5317
Statin medication, n (%) 618 (16.8)
Current smokers, n (%) 422 (11.5)
Type 2 diabetes, n (%) 421 (11.5)
Prevalent cardiovascular disease, n (%) 586 (15.9)
Physical activity index* 37.76.4
CESD score* 5.36.7
High sensitivity CRP, mg/L, median
(interquartile range)*
2.0 (1.0, 4.9)
BNP, ng/L, median (interquartile range)* 7.7 (4.0, 16.5)
Serum BDNF, ng/mL 23.5 (8.3)
Quartile 1, mean (range) 1.7–17.8
Quartile 2, mean (range) 17.9–23.2
Quartile 3, mean (range) 23.2–28.8
Quartile 4, mean (range) 28.8–64.9
Values are meanSD unless indicated otherwise. HDL indicates high-density lipoprotein;
CESD, Center of Epidemiological Study–Depression Scale; CRP, C-reactive protein; BNP,
B-type natriuretic peptide; BDNF indicates brain-derived neurotrophic factor.
*Offspring cohort only (n=3018).
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Mendelian randomization experiment
Mendelian randomization is based on the fact that alleles of
genetic variants (here, rs6265, a known functional variant in
exon 2 of the BDNF gene) are transmitted randomly during
conception from the parents to their offspring.21 Because
rs6265 alters BDNF levels, individuals are randomly assigned
to genetically elevated or reduced BDNF levels.21,22 Impor-
tantly, the random allocation of alleles during meiosis is
independent of traditional CVD risk factors and the CVD
disease process itself. Therefore, estimates from Mendelian
randomization studies are insensitive to (nongenetic) con-
founders and reverse causality.23 Thus, if lower BDNF levels
cause CVD, one can estimate the predicted relative CVD risk
increase that goes along with genetically reduced BDNF
levels, based on (1) the association of rs6265 with circulating
BDNF levels and (2) the association of circulating BDNF levels
with incident CVD. Accordingly, ﬁrst we related the SNP
rs6265 to circulating BDNF levels by using a linear regression
model (adjusted for age and sex) assuming an additive
genetic model. Next, based on the association of the SNP
with BDNF levels, and in turn the association between
circulating BDNF levels and incident CVD, we estimated the
predicted strength of association between SNP rs6265 and
CVD in age- and sex-adjusted Cox regression models. Third,
we evaluated the strength of association of the SNP rs6265
with CAD in the CARDIoGRAM consortium.15 These analyses
were again performed adjusting for age and sex (prior to
meta-analysis). Last, we compared the predicted risk for CVD
(based on FHS data) for this SNP with the observed relative
risk for CAD in CARDIoGRAM by using the 2-sample t test.
Results
Study Sample
The characteristics of our study sample are provided in
Table 1. Our sample was middle-aged to elderly, with a
moderate cardiovascular risk proﬁle. Clinical characteristics,
stratiﬁed by later CVD event status, are listed in Table 2.
Participants with CVD events were older and had a more
adverse cardiovascular risk proﬁle than those without a
future event. The age- and sex-adjusted correlations of serum
BDNF levels with clinical cardiovascular risk factors are given
in Table 3.
Table 2. Baseline Characteristics of the Study Sample,
Stratiﬁed by Incident CVD Status During Follow-up
Characteristic at Baseline
Incident CVD During Follow-up
No (n=2574) Yes (n=467)
Age, y 6111 7210
Body mass index, kg/m2 27.85.3 28.25.3
Systolic blood pressure, mm Hg 12719 13920
Diastolic blood pressure, mm Hg 7410 7310
Antihypertensive medication, n (%) 724 (28) 222 (47)
Total cholesterol, mg/dL 20336 20337
HDL cholesterol, mg/dL 5517 5116
Statin medication, n (%) 313 (12) 79 (17)
Current smokers, n (%) 296 (12) 59 (13)
Type 2 diabetes, n (%) 207 (8) 71 (15)
Values are meanSD unless indicated otherwise. CVD indicates cardiovascular disease;
HDL, high-density lipoprotein.
Table 3. Correlation Between Serum BDNF and
Cardiovascular Risk Factors
Trait Correlation
Body mass index 0.011
Systolic blood pressure 0.013
Diastolic blood pressure 0.048*
Total cholesterol 0.086†
HDL cholesterol 0.006
Log CRP‡ 0.002
Log BNP‡ 0.062†
Data are age- and sex-adjusted partial Pearson correlation coefﬁcients. BDNF indicates
brain-derived neurotrophic factor; HDL, high-density lipoprotein; CRP, C-reactive protein;
BNP, brain natriuretic peptide.
*P<0.01, †P<0.001.
‡Offspring cohort only (n=3018).
Table 4. BDNF, Cardiovascular Events, and Mortality—Event
Rates by BDNF Quartiles
BDNF
No. of Events/
No. at Risk
Person-years
Follow-up
Incidence Rate per 1000
Person-years (SE)
Cardiovascular events
Quartile 1 133/737 5471 26.0 (2.3)
Quartile 2 129/746 5901 22.7 (2.1)
Quartile 3 109/757 6215 20.4 (2.0)
Quartile 4 96/801 6419 20.3 (2.2)
All-cause mortality
Quartile 1 257/921 7676 31.0 (1.9)
Quartile 2 237/922 8153 26.3 (1.7)
Quartile 3 182/922 8286 23.0 (1.7)
Quartile 4 159/922 8195 23.7 (1.9)
BDNF indicates brain-derived neurotrophic factor.
Standardized to the sex- and age- group (<60, 60–74, >=75 years) distribution of the
study sample.
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Serum BDNF and Incidence of CVD Events
The age- and sex-adjusted incidence rates for cardiovascular
events during a median follow-up of 8.5 years, stratiﬁed by
quartiles of BDNF, are provided in Table 4 (upper half). CVD
incidence decreased monotonically across quartiles of
BDNF. The results of the proportional hazards regression
models relating BDNF levels to CVD incidence are shown in
Table 5 (upper half) and Figure 1 (top panel). Each 1-SD
increase in serum BDNF was associated with a 9% to 12%
reduced hazard for CVD events. Subjects in the highest
quartile of BDNF had a 27% to 32% lower risk for
cardiovascular events compared with those in the lowest
BDNF quartile. Exploratory analyses additionally adjusting
for hsCRP and BNP showed similar results (Table 6). Also,
additional adjustment for physical activity index and depres-
sive symptoms (using a CESD score ≥16 to deﬁne
depression) did not alter our results (hazard ratio for
incident CVD per 1-SD increase in BDNF 0.86, 95% CI 0.76
to 0.97; P=0.01). To further assess the role of smoking
behavior, we adjusted our multivariable models for lifetime
smoking exposure in pack-years, which did not inﬂuence our
ﬁndings (data not shown). Similarly, effect estimates did not
differ between smokers and nonsmokers (P>0.05 for
interaction; data not shown).
In multivariable-adjusted splines (Figure 2, top panel),
serum BDNF was linearly and inversely associated with CVD
risk.
Serum BDNF and All-Cause Mortality
The age- and sex-adjusted incidence rates for all-cause
mortality during a median follow-up of 8.9 years, stratiﬁed by
quartiles of the BDNF distribution, are shown in Table 4 (lower
half). The results of the Cox regression models are displayed
in Table 5 (lower half) and Figure 1 (bottom panel). Each 1-SD
increase in BDNF was associated with a 13% to 14% reduced
hazard of death. Individuals in the highest quartile of BDNF
had a 26% to 29% lower risk of death compared with those in
Table 5. Serum BDNF, Cardiovascular Events, and Mortality—Cox Regression Models
Cardiovascular Events*
Age- and Sex-Adjusted Model Multivariable Model†
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Continuous trait
1-SD increase 0.91 (0.82 to 1.00) 0.045 0.88 (0.80 to 0.97) 0.01
Quartiles
Quartile 1 1.00 Referent 1.00 Referent
Quartile 2 0.90 (0.70 to 1.15) 0.39 0.92 (0.72 to 1.17) 0.48
Quartile 3 0.78 (0.60 to 1.00) 0.049 0.73 (0.56 to 0.95) 0.02
Quartile 4 0.73 (0.56 to 0.95) 0.02 0.68 (0.52 to 0.89) 0.005
Trend across quartiles 0.01 0.001
All-Cause Mortality
Age- and Sex-Adjusted Model Multivariable Model‡
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Continuous trait
1-SD increase 0.86 (0.79 to 0.92) <0.0001 0.87 (0.80 to 0.93) 0.0002
Quartiles
Quartile 1 1.00 Referent 1.00 Referent
Quartile 2 0.83 (0.69 to 0.99) 0.03 0.85 (0.71 to 1.02) 0.08
Quartile 3 0.69 (0.57 to 0.84) 0.0002 0.71 (0.58 to 0.86) 0.0006
Quartile 4 0.71 (0.59 to 0.87) 0.0009 0.74 (0.60 to 0.91) 0.004
Trend across quartiles <0.0001 0.0005
BDNF indicates brain-derived neurotrophic factor, cardiovascular disease.
*Models derived from 3041 individuals without CVD at baseline.
†Adjusted for age, sex, smoking, systolic blood pressure, hypertension treatment, total and high-density lipoprotein cholesterol, diabetes mellitus, and body mass index and stratiﬁed by
cohort status.
‡Adjusted for age, sex, smoking, systolic blood pressure, hypertension treatment, total and high-density lipoprotein cholesterol, diabetes mellitus, body mass index, and CVD at baseline
and stratiﬁed by cohort status.
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the lowest quartile. Our ﬁndings remained robust in models
additionally adjusting for hsCRP and BNP (Table 6) and for
physical activity index and the CESD score (hazard ratio for
death per 1-SD increase in BDNF=0.87, 95% CI 0.77 to 0.97;
P=0.02). Again, adjustment for life-time smoking exposure did
not alter ﬁndings (data not shown), nor did effect estimates
differ between smokers and nonsmokers (P>0.05 for interac-
tion).
Increasing serum BDNF showed a linear relationship with
lower all-cause mortality through most of the distribution of
values, although the relationship plateaued at the upper end
of the distribution (Figure 2, bottom panel).
BDNF and CVD Risk Prediction
BDNF did not signiﬁcantly increase the c-statistic of our
standard risk factor model for cardiovascular events (area
under the curve 0.756 versus 0.759, P=0.99). However, both
IDI (0.004, 95% CI 0.001 to 0.006, P<0.05) and category-free
NRI (0.198, 95% CI 0.049 to 0.352, P<0.05) were statistically
signiﬁcant. Similarly, serum BDNF did not improve the
c-statistic of our standard risk factor model for mortality
(area under the curve 0.793 versus 0.810, P=0.97); however,
IDI (0.005, 95% CI 0.002 to 0.008, P<0.05) and category-free
NRI (0.225, 95% CI 0.120 to 0.325, P<0.05) were statistically
signiﬁcant.
Mendelian Randomization
To assess whether the association between circulating
BDNF levels and CVD may be causal, we used a known
functional genetic variant in the BDNF gene (rs6265) and
performed a Mendelian randomization experiment as
detailed earlier.21
We genotyped rs6265 in 3089 Framingham participants
and assessed its association with circulating BDNF levels. By
assuming an additive genetic model and adjusting for age
and sex, each copy of the minor T allele was associated with
0.772 ng/mL higher BDNF levels (95% CI 0.242 to 1.303,
P=0.0043; Figure 3). Based on the effect estimate for the
association between circulating BDNF levels and incident
CVD reported earlier here (Table 5), an increase of
0.772 ng/mL in BDNF levels translates into a predicted
hazard ratio for CVD of 0.991 (95% CI 0.982 to 1.000,
P=0.045) per T allele. The actual observed age- and sex-
adjusted odds ratio for CAD associated with 1 T allele of
rs6265 in CARDIoGRAM was 0.957 (0.923 to 0.992,
P=0.016) and did not differ signiﬁcantly from the predicted
effect size derived from the Framingham cohort (P=0.062 for
difference between observed and predicted effect size;
Figure 3), suggesting that the association between BDNF
and CVD risk is likely causal.
Discussion
We prospectively investigated the relation of serum BDNF
concentrations with CVD events and mortality in a large
community-based sample. We observed that higher levels of
BDNF are associated with lower risk of both CVD events and
death, independent of standard risk factors, including markers
of low-grade inﬂammation, BMI, physical activity, and depres-
sion. Individuals in the highest quartile of BDNF had an 25%
to 30% lower adjusted risk for future CVD events and death
Figure 1. Age- and sex-adjusted cumulative incidence of car-
diovascular events (top panel) and all-cause mortality (bottom
panel), stratiﬁed by quartiles of serum BDNF. BDNF indicates
brain-derived neurotrophic factor; CVD, cardiovascular disease.
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compared with those in the lowest quartile. The biologic
plausibility, demonstration of a dose-response relation (in
quartile-based analyses and splines), consistency of associ-
ation across multiple analyses, the temporal relation (BDNF
levels were measured before the outcomes of interest), and
the results of the Mendelian randomization experiment are
consistent with the notion that the association is indeed a
causal one.24
Epidemiological Data on BDNF and CVD
Existing epidemiological data regarding the relation of circu-
lating BDNF concentrations with CVD and mortality are sparse
and inconclusive. A small case-control study of 31 patients
with acute coronary syndrome and 19 healthy controls
conducted by Manni and collegues observed lower plasma
levels of BDNF in the acute coronary syndrome cases
compared with the controls, possibly suggesting a protective
role of BDNF.25 Krabbe and collegues reported that plasma
BDNF was inversely associated with mortality in a sample of
188 elderly women.6 Recently, Jian and collegues investigated
plasma BDNF concentrations in 885 patients with angina.5
They observed a cross-sectional association of BDNF levels
with CVD risk factors in a protective direction. Furthermore,
higher BDNF levels were prospectively associated with a lower
incidence of major coronary events in their high-risk referral
sample.5 Recently, Hallden and collegues reported in a large
sample of smokers that a polymorphism in the BDNF
(rs4923461) gene is associated with all-cause and cardiovas-
cular mortality but not with incident CVD.26 Serum BDNF was
not measured in their study.
To our knowledge, our study is the ﬁrst prospective
analysis in a large community-based cohort demonstrating
that higher serum BDNF levels are associated with a
decreased risk for future CVD events and mortality.
Possible Mechanisms
BDNF, a member of the neurotrophin family, is involved in the
regulation of a broad range of physiological functions including
neuronal development and plasticity, food intake, and physical
activity.27 As noted earlier, heterozygous BDNF knockout mice
consume more food than do their wild-type littermates and are
obese.2 At the same time, these BDNF knockout mice are
hyperactive, not lethargic, despite their obesity. This observa-
tion has led to the concept that BDNF may be released in
response to a challenging environment with high locomotor and
intellectual requirements and scarce food.27 Altered BDNF
levels have been reported in various neuropsychiatric diseases;
for example, depression appears to be associated with
decreased serum BDNF concentrations.28
Besides its important role in neurobiology, there is
increasing evidence that BDNF is also involved in cardiovas-
cular health and atherosclerosis. BDNF is expressed in
vascular endothelial cells,29 macrophages, and smooth
muscle cells of atherosclerotic coronary arteries.7 In one
study, patients with unstable angina have been reported to
have increased BDNF levels in the coronary circulation
compared with individuals with stable angina, possibly
suggesting that BDNF may be involved in stability of the
atherosclerotic plaque.7 In the same study, BDNF adminis-
tration increased NAPD(H) oxidase activity of human coronary
artery smooth muscle cells in vitro, suggesting that BDNF may
indeed have a detrimental effect on plaque stability. Never-
theless, the clinical relevance of these observations remains
to be elucidated.
Table 6. Serum BDNF, Cardiovascular Events, and Mortality—Additional Adjustment for hsCRP and BNP
CVD Incidence* Mortality†
Hazards Ratio (95% CI) P Value Hazards Ratio (95% CI) P Value
Continuous trait
1-SD increase 0.85 (0.75 to 0.96) 0.007 0.84 (0.75 to 0.94) 0.002
Quartiles
Quartile 1 1.00 Referent 1.00 Referent
Quartile 2 0.95 (0.69 to 1.31) 0.76 0.81 (0.61 to 1.09) 0.17
Quartile 3 0.74 (0.52 to 1.03) 0.08 0.68 (0.49 to 0.94) 0.02
Quartile 4 0.60 (0.43 to 0.86) 0.005 0.69 (0.50 to 0.94) 0.02
Trend across quartiles 0.002 0.009
BDNF indicates brain-derived neurotrophic factor; BNP, brain natriuretic peptide; hsCRP, high-sensivity C-reactive protein; CVD, cardiovascular disease.
*Based on 270 events in 2439 participants of the Framingham Offspring cohort free of CVD at baseline. Models adjusted for age, sex, smoking, systolic blood pressure, hypertension
treatment, total and high-density lipoprotein cholesterol, diabetes mellitus, body mass index, hsCRP, and BNP.
†Based on 311 events in 2811 participants of the Framingham Offspring cohort. Models adjusted for age, sex, smoking, systolic blood pressure, hypertension treatment, total and high-
density lipoprotein cholesterol, diabetes mellitus, body mass index, prevalent CVD, hsCRP, and BNP.
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Conversely, BDNF has been shown to play a crucial role in
the development and maintenance of the cardiac vasculature.
BDNF deﬁciency in mice impairs the survival of endothelial
cells in myocardial arteries and capillaries, leading to early
postnatal death.3 Conditional BDNF knockout mice with
experimental myocardial infarction showed larger areas of
ﬁbrosis and impaired revascularization and, as a conse-
quence, greater impairment of systolic function than
controls.4 These differences appeared consequent to altered
expression of BDNF in the brain (not in the heart) in response
to the ischemic event, stimulated via cardiac afferent
autonomous nerves after myocardial infarction.
Of note, polymorphisms in the BDNF gene have been
associated with BMI in recent genome-wide association
studies.30 We, therefore, adjusted our multivariable models
for BMI and diabetes, which did not alter our ﬁndings,
rendering obesity an unlikely explanation for associations
observed in our study. Similarly, polymorphisms in the BDNF
gene have been associated with smoking behavior, with the
A/C Met allele at rs6265 associated with both lower BDNF
levels and a slightly increased risk of being a smoker.26,31
We therefore extensively investigated the potential impact of
smoking on our ﬁndings using different statistical
approaches. We did not ﬁnd evidence for a relevant role
of smoking in the relation between BDNF and CVD or
mortality.
Taken together, it seems feasible that circulating BDNF
levels are protective by maintaining vascular integrity and that
these protective systemic effects outweigh potential detri-
mental local effects on plaque stability.
We observed that higher BDNF levels are linearly associ-
ated with lower risk for CVD events, whereas the protective
association with all-cause mortality abates at higher BDNF
levels. This may suggest that the protective cardiovascular
effects of high BDNF levels may be counterbalanced by
potential detrimental effects on non-CVD; for example, high
BDNF levels may promote cancer cell growth.32
Clinical Implications
Our data indicate that measuring BDNF only marginally
improves cardiovascular risk prediction. BDNF measurements
did not improve the area under the receiver operating
characteristic curve (for cardiovascular events); only IDI and
NRI were nominally signiﬁcant. Thus, it is unlikely that serum
BDNF is of relevant clinical value for diagnosing or predicting
CVD. However, our ﬁndings may be of pathophysiological
interest. Indeed, modulating BDNF signaling may be a
promising therapeutic concept. Of note, the relatively modest
effect of SNP rs6265 on BDNF levels and CVD risk does not
necessarily translate into a trivial role of the BDNF protein in
the pathogenesis of CVD. In fact, most common SNPs
reported in recent genome-wide association studies have only
Figure 2. Relations of serum BDNF with cardiovascular events
(top panel) and all-cause mortality (bottom panel)—multivariable
adjusted spline regression. BDNF indicates brain-derived neuro-
trophic factor; CVD, cardiovascular disease.
Figure 3. Mendelian randomization experiment. BDNF indicates
brain-derived neurotrophic factor; CAD, coronary artery disease;
CVD, cardiovascular disease; HR, hazard ratio.
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modest effect sizes, but therapeutic modulation of the
respective proteins may have a far greater impact. For
example, SNP rs2479409 in PCSK9 is associated with an
2 mg/dL alteration in LDL cholesterol levels (per allele), but
PCSK9 antibodies lower LDL cholesterol by almost 60 mg/
dL.33,34
Given the pivotal role of BDNF in neuroplasticity, until now
therapeutic applications of BDNF (agonists) have mainly been
motivated by neurovascular and neurodegenerative diseases.
In this context, an oral selective BDNF agonist derived from
plant ﬂavonoids showed promising results in mouse models of
stroke and Parkinson’s disease.35 Further investigations are
warranted to clarify whether BDNF agonists or pharmacolog-
ical interventions aimed at increasing circulating BDNF may
be applicable for reducing cardiovascular risk. In particular, it
remains to be shown whether the potential cardioprotective
effects of BDNF outweigh the theoretical potential to promote
cancer growth.
Limitations
Some limitations of our investigation should be discussed.
Our FHS sample is primarily white of European ancestry and
middle-aged to elderly. We estimated association of SNP
rs6265 with serum BDNF in this homogeneous but age- and
ethnicity-restricted sample, whereas the association of the
SNP with CAD was explored in the far larger, and relatively
more heterogeneous, CARDIoGRAM consortium. Measuring
serum BDNF in CARDIoGRAM was not feasible. The effect size
for the SNP was somewhat stronger in CARDioGRAM relative
to that estimated in FHS (although the 2 were not statistically
different). This may be due to the possibility that the SNP
captures effects at a tissue level (as opposed to blood levels)
and likely reﬂects lifelong exposure as opposed to a single-
occasion peripheral blood measurement that may be more
susceptible to regression dilution bias. Moreover, our FHS
study sample is of limited size. We therefore a priori decided
to analyze a very broad end point to maximize statistical
power. Our study sample was not sufﬁciently powered to
derive meaningful results for speciﬁc cardiovascular end
points. Larger analyses will be necessary to address these
questions.
Conclusions
Higher serum BDNF is associated with a decreased risk of
cardiovascular events and mortality. Mendelian randomization
supports a causal protective effect of BDNF on CVD. If
conﬁrmed, our ﬁndings raise the possibility that pharmaco-
logical interventions aimed at increasing systemic BDNF
signaling may be a promising tool for modulating cardiovas-
cular risk.
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